Radioimmunotherapy and secondary leukemia: A case report-Reference-Cited by-同舟云学术

Radioimmunotherapy and secondary leukemia: A case report

Published:2010-01 Issue:1 Volume:34 Page:e1-e4
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Magni Michele,Di Nicola Massimo,Testi Adele,Cabras Antonello,Devizzi Liliana,Guidetti Anna,Matteucci Paola,Viviani Simonetta,Bonfante Valeria,Carniti Cristiana,Ricca Irene,Carbone Antonino,Carlo-Stella Carmelo,Gianni Alessandro M.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non Hodgkin's lymphoma;Cortelazzo;British Journal of Haematology,2001

2. High-dose 90Y ibritumomab tiuxetan with tandem stem-cell reinfusion: an innovative outpatient preparative regimen for autologous hematopoietic cell transplantation;Devizzi;Journal of Clinical Oncology,2008

3. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non Hodgkin's lymphoma;Krishnan;Journal of Clinical Oncology,2008

4. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non Hodgkin's lymphoma;Witzig;Journal of Clinical Oncology,2003

5. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non Hodgkin lymphoma treated with tositumomab and I131 tositumomab;Bennet;Blood,2005

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibodies for Nuclear Medicine Therapy;Therapeutic Nuclear Medicine;2012

2. Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia;Cancer;2011-05-12